Vaccine News and Research

Latest Vaccine News and Research

Alzheimer's vaccine - First evidence for efficacy

AFFiRiS' Alzheimer's vaccine candidate AD02 showed indicative evidence for potential efficacy in a phase I clinical trial. This was demonstrated by the analysis of the data from secondary clinical study endpoints.

12 Mar 2011

Flu pandemics may return & mutating strains: Studies

Scientists have warned that we have not seen the end of H1N1 swine flu that swept the globe in 2009/10. The strain of the virus could easily morph into a more transmissible form, while an older, mid-20th century virus could also come roaring back they say. Asian influenza, a H2N2 strain, first appeared in 1957 and killed one to four million people despite a major vaccination campaign. Studies have shown that most people today aged 50 or older retain some immunity to the virus, which continues to circulate in birds and swine. But the younger are more vulnerable they warn.

12 Mar 2011

Groundbreaking studies presented at Prostate Cancer Research Program's IMPaCT conference

Today, the nation's most prestigious minds in prostate cancer research unveiled the findings of their groundbreaking studies at the Prostate Cancer Research Program's (PCRP's) Innovative Minds in Prostate Cancer Today (IMPaCT) conference in Orlando, Florida.

11 Mar 2011

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010, and provided an update on recent clinical and corporate developments.

11 Mar 2011

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

The Cancer Immunotherapy Consortium, a program of the nonprofit Cancer Research Institute, will host its 2011 Scientific Colloquium March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD.

11 Mar 2011

Researchers concerned about use of mercury-based compound in inactivated flu vaccines

As the United Nations, the European Commission, and the United States Food and Drug Administration evaluate the health and environmental risks associated with mercury, a known neurotoxin, carcinogen, mutagen, teratogen, and immune-system disruptor, new research continues to fuel concerns about Thimerosal, a mercury-based compound used as a preservative in inactivated flu vaccines.

11 Mar 2011

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today the unblinding of the Phase I clinical trial results for the adult population for its proprietary inactivated vaccine against human enterovirus 71, which causes hand, foot, and mouth disease.

10 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, today announces that it has signed a Research and License Agreement with Crucell Holland B.V. the Dutch developer of vaccines and antibodies.

10 Mar 2011

Swine flu virus may evolve into a deadlier form

In the fall of 1917, a new strain of influenza swirled around the globe. At first, it resembled a typical flu epidemic: Most deaths occurred among the elderly, while younger people recovered quickly. However, in the summer of 1918, a deadlier version of the same virus began spreading, with disastrous consequence. In total, the pandemic killed at least 50 million people - about 3 percent of the world's population at the time.

10 Mar 2011

Opinions: Investing in science, technology; Indian public-private partnership for NTDs; U.S. global food security investments; Clinton's statements on PEPFAR; U.S. foreign aid; primary care

"Now is the time to support science and technology - especially in difficult economic times. It is the right thing to do, and it makes good economic sense," Alex Dehgan, science and technology adviser to the USAID administrator, and Kaitlin Christenson, coalition director for the Global Health Technologies Coalition, write in an opinion piece appearing on The Hill's "Congress Blog."

10 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

Also in global health news: Rights abuses in Myanmar; Indian malnutrition; Mali Global Fund grant; shift in USAID's programs in Afghanistan; Gates Foundation grant for vaccines

Human Rights Abuses Impacting Health Situation In Parts Of Myanmar, Study Says.

9 Mar 2011

USPTO grants new patent to Intellect's Alzheimer's vaccine

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office in relation to the Company's RECALL-VAXTM technology platform.

9 Mar 2011

$100 million in grants for medical research announced

More than $100 million in grants was announced this Tuesday for an ambitious research project that will try to find what makes cancer so hard to beat. This project received $21.3 million from the National Health and Medical Research Council grants.

8 Mar 2011

FDA says no cause for alarm on vaccines for meningitis and pneumonia

According to US health officials there are no reports that arouse new safety concerns over two children’s vaccines that have been suspended in Japan following the deaths of four babies.

7 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011

Advaxis CEO issues statement to shareholders regarding recent common stock transition

Thomas A. Moore, chairman and CEO of Advaxis, Inc., the live, attenuated Listeria monocytogenes vaccine company, has issued the following statement to shareholders regarding the recent transition to the OTCQB from the OTCBB:

5 Mar 2011

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

5 Mar 2011